Centers & Specialties

Cancer Center

Clinical Interests
  • Merkel cell carcinoma
  • Melanoma
  • Squamous cell carcinoma
  • Dermatology (general)
  • Cutaneous t-cell lymphoma
  • Cutaneous b-cell lymphoma
  • Basal cell carcinoma
  • Bullous (blistering) disorders
Medical Education
  • MD, PhD, UMASS Medical School
  • Residency, Brigham and Women's Hospital|Residency, Columbia University Medical Center
  • Fellowship, Beth Israel Deaconess Medical Center
Board Certifications
  • Dermatology
  • Internal Medicine
Existing Patients
Patient Gateway
Insurances Accepted
  • Aetna Health Inc.
  • AllWays Health (NHP) - ACD
  • AllWays Health (NHP) - PBO
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • BMC HealthNet Mass Health MCO/ACO
  • Cigna (PAL #'s)
  • Commonwealth Care Alliance
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - other
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • Maine Community Health Options (MCHO)
  • MassHealth
  • Medicare
  • Medicare - ACD
  • OSW - Rhode Island
  • OSW - Vermont
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group
Provider Gender


David M. Miller, MD, PhD is a board-certified Dermatologist and Internist, as well as a board-eligible Hematologist and Medical Oncologist. 

Dr. Miller graduated with Honors from Boston College where he earned a BA in Political Science.  He received his medical (MD) and PhD degree in Biomedical Sciences from the University of Massachusetts.  While at UMass, Dr. Miller received the American Diabetes Association Physician-Scientist Training Award for three consecutive years, a Fuller Foundation grant, and he was inducted into the Alpha Omega Honor Society.  He then completed a Dermatology residency at Columbia University Medical Center, followed by a residency in Internal Medicine at Brigham and Women's Hospital.  Following both residencies, Dr. Miller completed fellowship training in Hematology/Oncology at Beth Israel Deaconess Medical Center.

Dr. Miller belongs to several professional organizations, including the American Academy of Dermatology, Medical Dermatology Society, and the American Society of Clinical Oncology.  He has numerous peer-reviewed publications and he has presented his work at the Society for Investigative Dermatology, New York Academy of Medicine, and the American Academy of Dermatology.  He is also a reviewer for the British Journal of Dermatology, Journal of Investigative Dermatology, JAEDV, and Clinical Cancer Research.

His research is focused on developing novel therapies for advanced skin cancer.  He has received support for his research from the NIH in the form of a loan repayment award, a grant from the American Skin Association and the Paul Carbone, MD fellowship award from ECOG-ACRIN. Dr. Miller's clinical interests include cutaneous oncology with a focus on the detection and treatment of high-risk skin cancers, Merkel cell carcinoma, melanoma, cutaneous lymphoma, general and complex medical dermatology.

Research & Publications


View my most recent publications at PubMed

Select Publications:

  • Eliades P, Abraham B, Ji Z, Miller DM, et al. High MITF Expression is Associated with Super-enhancers and Suppressed by CDK7 Inhibition in Melanoma. Journal Investigative Dermatology. 2018 Feb 2
  • Miller DM, et al. Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade. JAADCase Reports. 2017 Sep 8;3(5):412-415
  • Reddy B, Miller DM, Tsao H. Somatic driver mutations in melanoma. Cancer. 2017 Jun 1;123(S11):2104-2117
  • Eliades P*, Miller DM*, et al. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Cancer Biol Ther. 2016 Jul 2;17(7):778-784.
  • Miller DM, Flaherty KT, Tsao H. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. Seminars in Cutaneous Medicine and Surgery. 2014 Jun;33(2):60-7
  • Miller DM, Flaherty KT, Tsao H. Molecular Testing in Melanoma. Journal of the American Academy of Dermatology;2014 May;70(5):863-870
  • Miller DM, Flaherty KT. Cyclin-dependent kinases as therapeutic targets in melanoma. Pigment Cell and Melanoma Research; 2014 May;27(3):351-365


55 Fruit Street
Boston, MA 02114
Phone: 617-726-2914
Fax: 617-726-7768
Dermatology Associates
50 Staniford Street
2nd Floor
Boston, MA 02114-2517
Phone: 617-726-2914
Fax: 617-726-7768